Values | |
---|---|
Mean | 70 |
Standard deviation | 8.9 |
Median | 71 |
Interquartile range | 11.5 |
Mininum | 48 |
Maximum | 87 |
No. Cases (%) | |
---|---|
Male | 60 (61) |
Female | 39 (39) |
No. Cases (%) | |
---|---|
Pelvis | 45 (45) |
Ureter | 50 (51) |
Pelvis-ureter | 4 (4) |
No. Cases (%) | |
---|---|
pTa | 19 (19) |
pT1 | 18 (18) |
pT2 | 8 (8) |
pT3 | 48 (48) |
pT4 | 6 (6) |
No. Cases (%) | |
---|---|
Low pT (pT0-pT2) | 45 (45) |
High pT (pT3-pT4) | 54 (55) |
No. Cases (%) | |
---|---|
Grade 1 | 7 (7) |
Grade 2 | 39 (39) |
Grade 3 | 53 (54) |
No. Cases (%) | |
---|---|
Low grade | 15 (15) |
High grade | 84 (85) |
No. Cases (%) | |
---|---|
No Lymph node metastasis | 84 (88) |
Lymph node mestastasis | 12 (12) |
No. Cases (%) | |
---|---|
No lymphovascular invasion | 59 (60) |
Lymphovascular invasion | 40 (40) |
Values | |
---|---|
Mean | 54.8 |
Standard deviation | 39.9 |
Median | 47 |
Interquartile range | 56.5 |
Mininum | 3 |
Maximum | 173 |
No. Cases (%) | |
---|---|
No tumor recurrence | 65 (67) |
Tumor recurrence | 32 (33) |
No. Cases (%) | |
---|---|
No tumor progression | 34 (41) |
Tumor progression | 49 (59) |
No. Cases (%) | |
---|---|
AWD | 5 (5) |
DOC | 3 (3) |
DOD | 30 (30) |
LFU | 23 (23) |
NED | 38 (38) |
No. Cases (%) | |
---|---|
NED + AWD + LFU | 66 (67) |
DOC + DOD | 33 (33) |